All companies
Genus Plc logo

What smart money is saying about Genus PlcUnited Kingdom flag

GNS.L · Healthcare · Biotechnology

2 funds in our archive have pitched Genus Plc — most recently Greenwood Investors in December 2025.

Company profile

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in reproductive, and other technical services to farmers. Genus plc has a strategic collaboration with Beijing Capital Agribusiness Co. Ltd to pursue the porcine reproductive respiratory syndrome virus resistant regulatory and development work in China. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Fund coverage · 2 theses

  • Greenwood Investors
    December 2025

    Genus Plc is a dominant, asset-light animal genetics company with recurring revenues, newly de-risked gene-editing optionality, and a China JV that accelerates commercialization and delevers the balance sheet.

    Read the full thesis
  • Ennismore Global Equity Fund
    July 2025

    Genus Plc is a compelling investment opportunity due to its strong market position in pig genetics, predictable revenue growth from a royalty model, and significant upside potential from exclusive gene-editing technology.

    Read the full thesis

Read every full thesis on Genus Plc

Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans